Tysabri (tie-SAB-ree), the latest treatment for multiple sclerosis (MS)

January 2005

There's a lot of excitement about Tysabri (tie-SAB-ree), the latest treatment for multiple sclerosis (MS).

Tysabri (natalizumab) is a monoclonal antibody. It blocks immune cells from entering the CNS and attacking nerves.

It seems to be more effective than the other MS drugs... but it also costs more.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

raising questions about FDA's drug approval and surveillance process
Diabetes Reps will be touting evidence that suggests carvedilol is better than metoprolol for diabetes patients
Fibromyalgia what really works for fibromyalgia
Cardiology Reps will be saying that amlodipine (Norvasc) reduces the risk of cardiovascular events
Cardiology BiDil will be the first drug approved specifically for African Americans
Light therapy is often as effective as antidepressants for seasonal affective disorder (SAD)
Ritalin, Adderall, and other stimulants to enhance test scores
Antiarrhythmics flecainide (Tambocor) or propafenone (Rythmol) written "take as needed for atrial fibrillation"
Multiple Sclerosis Tysabri (tie-SAB-ree), the latest treatment for multiple sclerosis (MS)
Multiple Sclerosis Aricept and other cholinesterase inhibitors for patients with multiple sclerosis
Women's Health the risk of bone loss in women using Depo-Provera
Women's Health whether testosterone is appropriate for treating sexual dysfunction in women
Hematology & Oncology More women with EARLY breast cancer will be treated with an aromatase inhibitor
Hematology & Oncology Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)
Supplements DHEA for weight loss
Practice End of year is a good time to reflect on trustworthy drug information that is relevant to practice.